After the start of GLP-1RA treatment, participants were deemed to have discontinued the drug if they did not receive a refill for 90 days after their prescription ended
Genetic insights can support a more informed conversation with your provider about whether GLP-1 therapy is appropriate and which formulation (oral, injection, microdose) may align best with your genetic profile and clinical presentation
7: WASTAGE NOT REPORTED Since January 2017, Medicare has required the use of modifier -JW to indicate measurable drug wastage of 1 unit or greater
TB-500 (thymosin beta-4 fragment) is studied for its involvement in actin-binding protein regulation, cell migration dynamics, and cytoskeletal organization
These microneedles allow quick ATP sampling and detection, providing visual identification with high sensitivity, marking a significant advancement in ATP-sensing technologies
Furthermore, GLP-1 RAs seem to have similar safety profile in the IBD population to the one observed in the general population, based on real-world observations